Background: There is growing momentum worldwide for assisted dying. In Australia, voluntary assisted dying may occur in any setting, including an intensive care unit (ICU). As the subject of much debate worldwide, exploring ICU clinicians' perceptions of assisted dying is essential.

Aim: The aim of this study was to explore clinicians' perceptions of and preparedness for voluntary assisted dying in the ICU.

Method: An exploratory qualitative descriptive design using individual interviews was used. Medical, nursing, and allied health clinicians from three ICUs were recruited. Interviews were conducted between Nov 2022 and Jan 2023, with a hypothetical scenario about voluntary assisted dying used to prompt discussion. Interviews were recorded, professionally transcribed, and analysed using inductive content analysis.

Findings: ICU registered nurses (n = 20), physicians (n = 2), and allied health clinicians (n = 4) participated with interviews lasting 18-45 min (mean: 28 min). Analysis revealed four themes: (i) purpose of ICU reflected that ICU care was not all about saving lives, yet recognising dying and changing priorities was challenging; (ii) dying in the ICU is complex due to difficulties in talking about dying, accepting death as the outcome and evaluating care efficacy; (iii) voluntary assisted dying is a lot of grey because of perceived clinical and ethicolegal challenges; and finally, (iv) respecting choice was about respecting patients' values, beliefs, and autonomy, as well as clinicians' beliefs and right to exercise autonomy through conscientious objection.

Conclusion: Dying and death are inevitable, and views and perspectives about assisted dying will continue to evolve. Respecting patient choice is at the core of assisted dying, but respecting clinicians' perspectives and choice is equally important. With voluntary assisted dying now legal in all Australian states, ensuring ICU team and individual clinician preparedness through access to education, resources, and specialist support services is key to raising awareness and easing uncertainty about deaths through voluntary assisted dying.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aucc.2024.05.007DOI Listing

Publication Analysis

Top Keywords

assisted dying
44
voluntary assisted
28
dying
15
intensive care
12
clinicians' perceptions
12
assisted
11
care unit
8
allied health
8
health clinicians
8
voluntary
7

Similar Publications

Article Synopsis
  • The paper discusses factors influencing the increased accessibility of medical assistance in dying (MAID) in Canada since its legalization in 2016.
  • It highlights the impact of vague legislative language, effective referral policies, centralized clinical services, and enhanced public awareness on the uptake of MAID.
  • The authors conclude by examining how these factors intersect to shape the ethical and moral complexities surrounding MAID accessibility.
View Article and Find Full Text PDF

Beuthin and Bruce's study 'MAiD as human connection: Stories and metaphors of physician providers existential lived experience' in this journal describes the affective experiences of Canadian Medical Assistance in Dying (MAiD) providers. A critical response to this work shows it is based on flawed premises and interpretations of its data, which centers on praising its participants in lethal injection for their very positive emotions. Their study also seems to unproblematically construct people dying by MAiD as "the other," a term that usually describes members of groups subject to individual and systemic oppression.

View Article and Find Full Text PDF

Nanoparticle-Mediated Explosive Anti-PD-L1 Factory Built in Tumor for Advanced Immunotherapy.

Adv Mater

January 2025

Department of Chemistry, POSTECH-CATHOLIC Biomedical Engineering Institute, Pohang University of Science and Technology (POSTECH), Pohang, 37673, Republic of Korea.

Immunotherapy, particularly immune checkpoint blockade (ICB) therapies, has revolutionized oncology. However, it encounters challenges such as inadequate drug accumulation and limited efficacy against "cold" tumors characterized by lack of T cell infiltration and immunosuppressive microenvironments. Here, a controlled antibody production and releasing nanoparticle (CAPRN) is introduced, designed to augment ICB efficacy by facilitating tumor-targeted antibody production and inducing photodynamic cell death.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!